123018-23-5

Basic information

• Product Name: 7-Methanesulfonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine
• Synonyms: 7-Methanesulfonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine
• CAS NO: 123018-23-5
• Molecular Formula: C₁₁H₁₅NO₂S
• Molecular Weight: 225
• Mol File: 123018-23-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 426.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.174±0.06 g/cm3(Predicted)
• PKA: 9.53±0.20(Predicted)
• CAS DataBase Reference: 7-Methanesulfonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Methanesulfonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine(123018-23-5)
• EPA Substance Registry System: 7-Methanesulfonyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine(123018-23-5)

Safety Data

• Hazardous Substances Data: 123018-23-5(Hazardous Substances Data)

Upstream product

• 123462-52-2 3-acetyl-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 4424-20-8 2,3,4,5-tetrahydro-1H-3-benzazepine 
• 35760-18-0 3-acetyl-7-chlorosulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 10533-22-9 1-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone 
• 613-73-0 1,2-phenylenediacetonitrile 

Downstream Products

• 264264-44-0 trans-3-(2-(4-(N-tert-butoxycarbonylamino)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 264264-45-1 trans-3-(2-(4-aminocyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine 

Relevant articles and documents

NOVEL COMPOUNDS OF AMINO SULFONYL DERIVATIVES

The present invention relates to compounds with formula (I) or a pharmaceutically acceptable salt thereof: (I);wherein; T is a (4 to 10)-membered heterocyclyl and wherein R1, R2 and R3 are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of the 11-β-hsd-1 enzyme.

Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)

The invention provides compounds of formula (I): wherein: R2 and R3 independently represent various substituents; R1 and R4 independently represent H, F, Cl, Br, Cl1-2alkyl, C1alkoxy, OH, CN, or NO2; B represents a sulfur atom or a —CH2-group; t represents 3 or 4; and A represents an optionally substituted 5- or 6-membered aromatic heterocyclic ring, or an optionally substituted bicyclic heterocyclic ring system in which at least the ring bound to the group B in Formula (I) is aromatic; or a salt thereof. Preferably, A is selected from one of the groups (i), (ii) or (iii): wherein X1 and X2 are independently N or CR8, and X3 is NR8, O or S; Y1 and Y3 are independently N or CR9, and Y2 is NR9, O or S; Z1 is NR10, O or S, and Z2 and Z3 are independently N or CR10; R8, R9, and R10 are as herein defined, and R7 is H, a halogen atom, OH, cyano, nitro, C1-4alkyl, C1-4alkoxy, C1-4alkylenedioxy, C1-4alkanoyl, or C1-4alkylsulfonyl, an optionally substituted 3-, 4-, 5- or 6-membered cycloalkyl ring, or a group of the formula (a), (b), (c) or (d) as defined by the formulas (a), (b), (c) or (d). The compounds are modulators of dopamine D3 receptors and have potential in the treatment of psychotic conditions (e.g. schizophrenia) or substance abuse.

Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders

Sulfinyl and sulfonyl substituted 3-benzazepine compounds are useful in treating gastrointestinal motility disorders and emesis. A particular compound of this invention is 7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine.